All News
ACR21 Best Abstracts - Day 4
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.
Read Article
Predictors of Remission and Low Disease Activity in SLE
A treat-to-target strategy has been shown to improve clinical outcomes in patients with rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis including systemic lupus erythematosus. The goal of treatment in SLE is aimed at remission or low disease activit
Read Article
Management of Pain in Spondyloarthritis: Dr. Antoni Chan ( @synovialjoints ) discusses abstract #0360 presented at the #ACR21 annual meeting.
https://t.co/C6QU1J6E18 https://t.co/EAfXarQ976
Links:
Dr. John Cush RheumNow ( View Tweet)
Iberdomide for Lupus: Dr. Kathryn Dao ( @KDAO2011 ) discusses abstract #1458 presented at the #ACR21 annual meeting.
https://t.co/viLtTG0tzB https://t.co/rdWTXaquDS
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKi For Refractory Still’s Disease: Dr. Olga Petryna ( @DrPetryna) discusses abstract #0195 presented at the #ACR21 annual meeting.
https://t.co/deSxncZOVP https://t.co/OJWGd4Osc4
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Additional analysis on Phase 2 trial of Deucravacitinib (Tyk-2 inhibitor) in PsA. n=203 (dose 6mg QD v 12mg QD v Placebo)
🔹Prior-TNF vs TNF-naive: similar
Significant improvement:
🔹ACR 20/50/70 & HAQ-DI
🔹TJC/SJC/enthesitis
https://t.co/RV1zLpkUQe
#ACR21 Abst#1820 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Study presented by Dr. Michaela Koehm evaluated benefit of MTX in combination with ustekinmuab in PsA w/1° outcome of non-inferiority to placebo @ DAS28 @ wk 24.
🔹Randomized 173 pts
🔹52 weeks
🔹1° met
(continued below)
https://t.co/65ZXDjG9ur
#ACR21 Abst#L12 @RheumNow https://t.co/KsBbwJuLe8
Pedro Castillo _Castillo_Pedro ( View Tweet)
Glucocorticoids (GC) in SLE on Belimumab
🔹Post-hoc, 5 phase 3 trials
🔹1° endpoint >25% pred↘️ to <7.5mg/d
🔹BEL n=1869; Placebo n=1217
🔹Baseline: 88% on GC; mean ~12.3mg/d pred
🔹Endpoint met by 17% BEL and 12% Pbo (p=0.0024)
https://t.co/xp9LamlpHZ
#ACR21 Abst#1283 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
#ICYMI #ACR21
Watch my interview with @LatikaGupta_ as she discusses the CoVAD study.
@RheumNow @APLAR_org @rheumarhyme https://t.co/et0X7ltx3K
sheila RHEUMarampa ( View Tweet)
The amazing team @RheumNow and Dr.Kavanaugh are reviewing abstracts. #ACR21
https://t.co/kz8Y5mEgPN https://t.co/n0NMQ0P9uU
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
My Interview with Dr. Seoyoung Kim
👉🏼why/how she got into research
👉🏼her studies on CV risk w/HCQ, real world evidence CV risk w/Tofacitinib, gout T2T MACE occurrence @rheumnow #acr21
https://t.co/RjW5yfyWF6 via @YouTube
TheDaoIndex KDAO2011 ( View Tweet)
Day 1 Report from #ACR21
The first full day of Abstracts and Presentations from ACR Convergence, the 2021 Virtual meeting, was full of highly engaging sessions, quality posters and unique presentations.
https://t.co/hhuGBe8dwr https://t.co/I5dCzFd9SJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Dellaripa w/great talk on digital ischemia.
Presents case of 25 yo F w/SLE, Class IV LN, APS, on apixaban, MMF, HCQ admitted w/AKI, ⬆️Upro & U-blood
-> new HFrEF (EF 22%), tachy, & digital ischemia w/skin bx = thrombotic vasculopathy.
#ACR21 Scientific Session 9T114 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Had a blast with the @RheumNow team covering #ACR21! Eager to pour over more material over the coming weeks. What did folks do before the abstracts and videos were available online??
Pedro Castillo _Castillo_Pedro ( View Tweet)
Third Time's the Charm - COVID Vaccination While on Rituximab: Dr. Yuz Y... https://t.co/uxA00n1hxy via @YouTube Do watch my short commentary on the enhanced immuno-protection of 3rd primary #COVID dose in patients who are treated with rituximab #ACR21 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Risk of retinopathy vs #lupus flares. Do watch my interview with Dr Jorge on her works on issues surrounding hydroxyxhloroquine dose #ACR21 @RheumNow https://t.co/hKsAi4dD2n
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Watch the @RheumNow #rheumatoidarthritis panel discuss some of our highlights from #ACR21!
https://t.co/Q5Yps3s165
Mrinalini Dey DrMiniDey ( View Tweet)
Do watch the Autoinflammatory Faculty @RheumNow discussed a selection of data presented at #ACR21 @uptoTate @bella_mehta @DrPetryna
Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in i... https://t.co/4biuKzWLBc via @YouTube
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Impromptu #TeamSparks video meeting with 2nd year fellows @KronzerMD and Dr Gregory McDermott detailing our research findings from the @MassGenBrigham Biobank (funded by @NIH_NIAMS and VERITY) @OrACORe_BWH @MayoClinic @RheumNow #ACR21
https://t.co/CQ9XDamb0E
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
